Surgical procedures company Olympus Corporation of the Americas revealed on Tuesday the launch of a definitive agreement to acquire the lithotripsy system design and production technology from Cybersonics Inc, based in Erie, PA.

In conjunction, Olympus' dual action lithotripsy system ShockPulse-SE and CyberWand, currently manufactured by Cybersonics, will now be part of Olympus' urology competence.

Via this acquisition, Olympus will further improve clinical outcomes, reduce overall costs as well as enhance quality of life for patients.

The intracorporeal lithotripsy has long proven to be an effective, less invasive method for breaking up stones in the kidney, bladder or ureter. CyberWand is a dual probe electromechanical device capable of fragmenting and aspirating calculi in the kidney, bladder or ureter. ShockPulse-SE, a dual action lithotripter, simultaneously produces both a constant ultrasonic wave and intermittent shockwave energy via a single probe to greatly reduce procedure time.

Both ShockPulse-SE and CyberWand will be serviced and manufactured by Olympus' subsidiary, Olympus Surgical Technologies America (OSTA).

Financial details of the agreement were not disclosed by the companies.